These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12610519)

  • 1. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
    van Etten B; de Vries MR; van IJken MG; Lans TE; Guetens G; Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Br J Cancer; 2003 Jan; 88(2):314-9. PubMed ID: 12610519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
    van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
    J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
    van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
    Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
    Nooijen PT; Manusama ER; Eggermont AM; Schalkwijk L; Stavast J; Marquet RL; de Waal RM; Ruiter DJ
    Br J Cancer; 1996 Dec; 74(12):1908-15. PubMed ID: 8980389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
    Seynhaeve AL; de Wilt JH; van Tiel ST; Eggermont AM; ten Hagen TL
    Br J Cancer; 2002 Apr; 86(7):1174-9. PubMed ID: 11953868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
    de Wilt JH; ten Hagen TL; de Boeck G; van Tiel ST; de Bruijn EA; Eggermont AM
    Br J Cancer; 2000 Mar; 82(5):1000-3. PubMed ID: 10737379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.
    Manusama ER; Nooijen PT; Stavast J; Durante NM; Marquet RL; Eggermont AM
    Br J Surg; 1996 Apr; 83(4):551-5. PubMed ID: 8665257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
    de Wilt JH; Manusama ER; van Tiel ST; van Ijken MG; ten Hagen TL; Eggermont AM
    Br J Cancer; 1999 Apr; 80(1-2):161-6. PubMed ID: 10389992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
    Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
    Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach.
    Manusama ER; Stavast J; Durante NM; Marquet RL; Eggermont AM
    Eur J Surg Oncol; 1996 Apr; 22(2):152-7. PubMed ID: 8608832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
    de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
    Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
    de Wilt JH; Manusama ER; van Etten B; van Tiel ST; Jorna AS; Seynhaeve AL; ten Hagen TL; Eggermont AM
    Br J Cancer; 2000 Nov; 83(9):1176-82. PubMed ID: 11027431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
    Borel Rinkes IH; de Vries MR; Jonker AM; Swaak TJ; Hack CE; Nooyen PT; Wiggers T; Eggermont AM
    Br J Cancer; 1997; 75(10):1447-53. PubMed ID: 9166936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
    van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
    Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
    De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM
    Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.
    Brunstein F; Eggermont AM; de Wiel-Ambagtsheer Ga; van Tiel ST; Rens J; ten Hagen TL
    Ann Surg Oncol; 2007 Feb; 14(2):795-801. PubMed ID: 17096052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
    Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
    Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.